Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipNST provided quality review for a broad range of regulatory documents, including:
We were also contracted to provide medical writing and editorial support as well as general QX function for all regulatory submission documents.
Founded in 2008, Adaptimmune specialises in developing novel therapies for the treatment of resistant tumour types, exploiting their proprietary cell therapy platform which harnesses a patient's own cells. Adaptimmune engineers the patient’s T-cell receptors (TCRs) so that they identify cancer proteins for target therapy. The company received US FDA approval for TECELRA® in 2024, becoming the first engineered cell therapy for solid tumour cancers. The company has since been researching multiple novel therapies for a variety of cancer types.
NST began work with Adaptimmune in 2024, conducting a QC review of an IB update for uzatresgene autoleucel, one of Adaptimmune’s TCR-based therapies. NST went onto play a pivotal role with the team responsible for the delivery of Adaptimmune’s regulatory documents. Adaptimmune appreciated NST’s flexibility and range of skills, meaning assistance could be scaled to address any of their medical writing needs across a broad range of regulatory documents for their various development assets.
NST established clear lines of communication with the Adaptimmune team to enable close tracking of multiple documents across a variety of projects with ambitious timelines. All documents were delivered to the highest quality and according to the agreed timelines.